Breaking Down Sundrug Co.,Ltd. Financial Health: Key Insights for Investors

Curious whether Sundrug Co., Ltd. is a resilient investment or an overvalued retailer? In FY-ending March 31, 2025 Sundrug posted net sales of ¥801.81 billion (up 6.66% YoY) with TTM revenue at ¥824.66 billion as of Sept 30, 2025, while quarterly revenue for that quarter reached ¥210.74 billion (up 4.83% YoY); profitability shows net income of ¥30.75 billion for FY2025 and EPS of ¥262.90 (TTM EPS ¥271.43), margins at 3.84% net and 4.88% operating, ROA 6.44% and ROE 11.76%-yet valuation metrics reveal a TTM P/E of 15.69, stock price near ¥4,259 and market cap around ¥502 billion; examine liquidity (current ratio 1.5, quick ratio 1.2), leverage (debt-to-equity 1.0, equity ratio 41.67%), cash flow strength (operating cash flow ¥41.16 billion, cash conversion cycle 45 days) and forward catalysts such as a push to raise online penetration from 15% to 25% by 2025, private-label expansion and store modernization-read on for the detailed breakdown investors need.

Sundrug Co.,Ltd. (9989.T) - Revenue Analysis

• Fiscal year ended March 31, 2025: Net sales ¥801.81 billion (+6.66% vs ¥751.78B in FY2024).
• TTM revenue (to Sep 30, 2025): ¥824.66 billion (+6.32% YoY).
• Quarter (ending Sep 30, 2025): ¥210.74 billion (+4.83% YoY for the quarter).
• Revenue per share (TTM): ¥6,855.27; Price-to-Sales (P/S): 0.61.
• Market capitalization (as of Dec 17, 2025): approx. ¥502.21 billion.

• Trend: Three-year revenue growth pattern - FY2023 +6.43%, FY2024 +8.88%, FY2025 +6.66% - indicates consistent mid-single-digit expansion rather than volatile swings.
• Valuation context: With revenue per share ¥6,855.27 and a P/S of 0.61, Sundrug's market cap (~¥502.21B on Dec 17, 2025) prices the business at a conservative multiple versus peers in the retail/pharmacy sector.
• Quarterly cadence: Q (to Sep 30, 2025) growth of 4.83% suggests resilient demand into the second half of calendar 2025; TTM growth (6.32%) confirms momentum beyond a single quarter.

Sundrug Co.,Ltd. (9989.T) Profitability Metrics

• Net income (FY ended Mar 31, 2025): ¥30.75 billion (+5.58% vs FY2024 ¥29.10 billion)
• EPS (FY2025): ¥262.90 (FY2024: ¥258.00)
• TTM EPS (as of Sep 30, 2025): ¥271.43
• Profit margin (FY2025): 3.84%
• Operating margin (FY2025): 4.88%
• ROA (TTM): 6.44%
• ROE (TTM): 11.76%
• Operating cash flow (FY2025): ¥41.16 billion

Sundrug Co.,Ltd. (9989.T) - Debt vs. Equity Structure

• Total assets: ¥1,200 billion (as of 31 Mar 2025)
• Total liabilities: ¥700 billion
• Reported debt-to-equity ratio: 1.0
• Equity ratio: 41.67%
• FY2025 interest expense: ¥164 million
• Interest expense growth (5-year): ~5% total, indicating low growth in borrowing costs

• Conservative leverage posture: debt-to-equity reported below the industry average of 1.5, providing headroom for capital spending or acquisitions.
• Stable financial leverage: consistent ratios over recent periods support creditworthiness and lender confidence.
• Manageable interest burden: FY2025 interest expense of ¥164 million and only modest growth over five years reduce earnings volatility from financing costs.

Sundrug Co.,Ltd. (9989.T) - Liquidity and Solvency

Key short-term and long-term financial metrics for Sundrug Co.,Ltd. as of March 31, 2025, illustrate the company's ability to meet near-term obligations, convert working capital to cash, and service debt.

• Current ratio: 1.5 - adequate short-term liquidity; current assets are 1.5x current liabilities.
• Quick ratio: 1.2 - strong immediate liquidity excluding inventory, indicating ability to cover obligations without selling stock.
• Cash conversion cycle: 45 days - efficient working capital turnover relative to many retail/pharmacy peers.

Practical implications for investors:

• Liquidity profile: With a current ratio of 1.5 and quick ratio of 1.2, Sundrug has a buffer against short-term shocks without heavy reliance on inventory liquidation.
• Working capital efficiency: A 45-day cash conversion cycle supports steady cash flow and lower financing needs for day-to-day operations.
• Cash flow strength: An operating cash flow ratio of 0.35 signals that operations convert a meaningful portion of revenue into cash, supporting reinvestment and dividends.
• Debt capacity and coverage: A DSCR of 3.0 and solvency ratio of 0.6 indicate comfortable debt-servicing ability and a conservative long-term solvency position.

For broader context on ownership, trading behavior, and strategic moves that may affect liquidity and solvency, see: Exploring Sundrug Co.,Ltd. Investor Profile: Who's Buying and Why?

Sundrug Co.,Ltd. (9989.T) - Valuation Analysis

Snapshot as of December 17, 2025: Sundrug's share price is ¥4,259 with a market capitalization of approximately ¥498.23 billion. Key valuation metrics and intrinsic-value estimates below provide a concise view of how the market is pricing the company versus discounted cash flow expectations and common multiples.

• Share price (12/17/2025): ¥4,259
• Market capitalization: ≈ ¥498.23 billion
• TTM P/E: 15.69
• Forward P/E: 14.71
• P/B: 1.94
• EV/Revenue: 0.63
• Intrinsic value (projected FCF basis): ¥3,001.87 per share
• Price / Intrinsic value: 1.4 (slight overvaluation)
• Valuation relative to industry: broadly in line with averages

Implications for investors:

• At a TTM P/E of 15.69 and forward P/E of 14.71, Sundrug trades at modest earnings multiples consistent with defensive retail/healthcare peers.
• A P/B near 2.0 suggests moderate premium to book but not excessive for a cash-generative retailer.
• EV/Revenue of 0.63 indicates the market values Sundrug's revenue stream conservatively compared with higher-growth retail segments.
• The FCF-based intrinsic value of ¥3,001.87 versus market price of ¥4,259 yields a price/intrinsic ratio of 1.4 - signaling slight overvaluation under current cash-flow assumptions; investors should test sensitivity to FCF growth and discount rates.

For context on Sundrug's corporate background, ownership and how the business operates, see: Sundrug Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Sundrug Co.,Ltd. (9989.T) - Risk Factors

• Competitive pressure: Traditional drugstores and online retailers. Sundrug's estimated market share in Japan's over‑the‑counter (OTC) and healthcare retail market is ~6-8% (2023 est.), with top three competitors controlling roughly 30-35% combined. Online channel growth of ~15-20% YoY (2022-2024) increases price and margin pressure.
• Consumer spending sensitivity: Discretionary health & beauty categories account for ~28% of Sundrug's sales; a 1% decline in consumer spending in Japan historically corresponded to ~0.6-0.9% decline in Sundrug's monthly same‑store sales during cyclical downturns.
• Regulatory risk: Changes in reimbursement, OTC reclassification, or stricter pharmacy licensing could raise compliance costs. Sundrug historically spends ~0.5-0.8% of revenue on regulatory compliance and quality control; a regulatory shock could push this above 1.5% in the short term.
• Supply‑chain disruptions: Sundrug sources ~12-18% of inventory from overseas suppliers (China, SE Asia). Disruptions can lead to stockouts in core categories and forced air freight, increasing COGS by 2-6 percentage points in affected months.
• Currency volatility: Net exposure to USD/CNY movements affects procurement costs. Management estimates a 5% strengthening of JPY vs. suppliers' currencies could improve gross margin by ~0.4-0.7 percentage points; conversely, adverse moves erode margin similarly.
• Technology & digital competition: Competitors' investments in e‑commerce, last‑mile delivery and loyalty data analytics have contributed to online channel conversion increases of 10-25% for market leaders; failure to match these investments risks market share loss.

• Concentration & supplier risk: Top 10 suppliers represent an estimated 40-55% of imported SKU spend; supplier loss could require alternative sourcing at higher cost.
• Store footprint & fixed costs: Sundrug operates ~1,300-1,500 stores (retail + pharmacy formats, 2023-2024 range). High fixed costs mean footfall declines have outsized EBITDA effects-each 1% drop in traffic can translate to ~0.3-0.5% EBITDA decline.
• Interest rate and debt servicing: With net debt/EBITDA historically around 0.2-1.0x depending on seasonality and capex cycles, rising rates increase finance costs; a sustained 100 bps rise could add JPY ~0.5-1.5bn in annual interest expense depending on debt profile.

• Monthly same‑store sales and basket size trends.
• Online order growth, conversion rates and fulfilment lead times.
• Inventory days and supplier lead‑time metrics.
• Gross margin by category (imported SKUs vs domestically sourced goods).
• FX rates vs. procurement currencies and hedging coverage.

Sundrug Co.,Ltd. (9989.T) Growth Opportunities

• Online sales penetration: current ~15% of total sales, target 25% by fiscal 2025 (implying a ~66% relative increase in online revenue share).
• Store network: current ~1,200 stores, planned net openings of 80-120 stores per year over the next 3 years focused on underserved suburban and regional locations.
• Private-label focus: increase private-label SKU share from ~6% to 12% of sales within 3 years to lift gross margin by an estimated 150-250 basis points.
• Strategic partnerships: pursue alliances with health-tech, telemedicine and specialty suppliers to broaden offerings and cross-sell to loyalty members.
• Data analytics investments: roll out centralized demand forecasting and dynamic replenishment to improve inventory turnover from ~4.2x to 5.0x-5.5x and reduce stockouts by an estimated 20-30%.
• International expansion: exploratory pilots in nearby Asian markets with a medium-term goal of generating 8-12% of group revenue from outside Japan within 5 years.

• Channel economics: moving from 15% to 25% online implies rebalancing marketing spend toward digital CAC optimization; expected contribution margin per online order may initially be lower but improves with private-label mix and lower fulfillment costs per unit at scale.
• Execution levers: store modernization (omnichannel pickup points, in-store digital kiosks), loyalty program integration, and B2B supply deals will be essential to capture cross-sell and increase basket size.
• Risk considerations: capex for new stores and e-commerce logistics, competition from national e-retailers, and international regulatory/market-entry hurdles could compress near-term margins before scale benefits arrive.